Guía de práctica clínica mexicana para el diagnóstico y tratamiento de las dislipidemias y
enfermedad cardiovascular aterosclerótica SciELO - Scientific Electronic Library Online vol.92 …

Disorders of lipid metabolism. Clinical Guidelines 2023 | Ezhov | Russian Journal of
Cardiology Russian Journal of Cardiology eng | рус User ISSN 1560-4071 (Print) ISSN …

При участии: Национального общества по изучению атеросклероза (НОА), Российской
ассоциации эндокринологов (РАЭ), Российского общества кардиосоматической …

Background. Elevated plasma low‐density lipoprotein cholesterol (LDL‐C) is the main risk
factor for atherosclerotic cardiovascular disease (ASCVD). Statins are the drugs of choice for …

In 2023 there are still even 75% of patients over the target of low-density lipoprotein
cholesterol (LDL-C), and hypercholesterolemia is the most common and the worst monitored …

Aims European guidelines set low-density lipoprotein cholesterol (LDL-C) treatment goals<
1.4 mmol/L after acute coronary syndrome (ACS), and< 1.0 mmol/L for patients with …

Heterozygous familial hypercholesterolemia (HeFH) is a common autosomal-dominant
inherited disorder associated with atherosclerotic cardiovascular disease (ASCVD). HeFH …

Нарушения липидного обмена, или дислипидемии, включают целый спектр состояний,
когда концентрации липидов и липопротеинов крови выходят за пределы нормы …

Dyslipidemia is a significant risk factor for atherosclerotic cardiovascular disease (ASCVD),
and statins are the primary therapeutic options for reducing low-density lipoprotein …

Atherosclerotic cardiovascular disease poses a significant global health issue, with
dyslipidemia standing out as a major risk factor. In recent decades, lipid-lowering therapies …